{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Injectable",
    "query": {
      "condition": "Injectable"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3125,
    "total_pages": 313,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Injectable&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T20:36:34.219Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03949764",
      "title": "The Kentucky Viral Hepatitis Treatment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "Opioid-Related Disorders",
        "Injection Drug Use"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir/velpatasvir (Epclusa®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennifer Havens",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 374,
      "start_date": "2019-09-23",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 1,
      "location_summary": "Hazard, Kentucky",
      "locations": [
        {
          "city": "Hazard",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949764"
    },
    {
      "nct_id": "NCT03223298",
      "title": "Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Head",
        "Pain Syndrome",
        "Temporomandibular Disorder",
        "Myofascial Pain Syndrome",
        "Myofascial Pain"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type A",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2018-08-31",
      "completion_date": "2020-03-13",
      "has_results": true,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03223298"
    },
    {
      "nct_id": "NCT05813678",
      "title": "A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Phenylketonuria (PKU)"
      ],
      "interventions": [
        {
          "name": "Pegvaliase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 450,
      "start_date": "2022-06-06",
      "completion_date": "2033-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05813678"
    },
    {
      "nct_id": "NCT03014635",
      "title": "Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxins, Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebos",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Revance Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 306,
      "start_date": "2016-12-05",
      "completion_date": "2017-11-03",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 9,
      "location_summary": "Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Naperville",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014635"
    },
    {
      "nct_id": "NCT06518928",
      "title": "SprmPik AI Sperm Selection Study SiD, an Assistant for Sperm Selection During Intracytoplasmic Sperm Injection in Medically Assisted Reproduction: Effect on Fertilization, Blastocyst Formation, Early Pregnancy Loss, and Consistent Practice. A Prospective Pilot Study.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "Artificial Intelligence assisted sperm selection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ovation Fertility",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 155,
      "start_date": "2024-01-01",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2024-07-25",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • Austin, Texas",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06518928"
    },
    {
      "nct_id": "NCT03429049",
      "title": "A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "CNTX-4975-05",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centrexion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "40 Years to 95 Years"
      },
      "enrollment_count": 332,
      "start_date": "2018-01-24",
      "completion_date": "2019-11-22",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03429049"
    },
    {
      "nct_id": "NCT04629664",
      "title": "FX-322 in Adults With Severe Sensorineural Hearing Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hearing Loss, Sensorineural",
        "Noise Induced Hearing Loss",
        "Sudden Hearing Loss"
      ],
      "interventions": [
        {
          "name": "FX-322",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Frequency Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2020-11-02",
      "completion_date": "2021-09-20",
      "has_results": false,
      "last_update_posted_date": "2022-02-01",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 7,
      "location_summary": "Novi, Michigan • Omaha, Nebraska • Amherst, New York + 3 more",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Orangeburg",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04629664"
    },
    {
      "nct_id": "NCT03886948",
      "title": "A Study of Injections of LY3074828 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3074828",
          "type": "DRUG"
        },
        {
          "name": "Pre-filled syringe (PFS)",
          "type": "DEVICE"
        },
        {
          "name": "Autoinjector (AI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2019-03-27",
      "completion_date": "2019-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03886948"
    },
    {
      "nct_id": "NCT01523067",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Vasomera (PB1046)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01523067"
    },
    {
      "nct_id": "NCT03728309",
      "title": "JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin Smoothness of the Cheeks"
      ],
      "interventions": [
        {
          "name": "JUVÉDERM VOLITE™ XC",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2018-11-09",
      "completion_date": "2020-07-17",
      "has_results": true,
      "last_update_posted_date": "2022-12-19",
      "last_synced_at": "2026-07-21T20:36:34.219Z",
      "location_count": 13,
      "location_summary": "Fresno, California • Los Angeles, California • Santa Monica, California + 10 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Solana Beach",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03728309"
    }
  ]
}